Neptune Technologies & Bioresources Inc (NEPT) 2.34 $NEPT
Neptune to Hold Conference Call to Discuss Fourth Quarter and Fiscal Year Results
GlobeNewswire - 2 hrs 58 mins ago
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation"
(Nasdaq:NEPT) (TSX:NTB), announced today that it will be holding a conference call on Thursday May 22 at 9:00 AM (ET) to present its results for the fourth quarter and fiscal year ended February 28, 2014.
Neptune Receives CSST Report
GlobeNewswire - Thu May 08, 9:53AM CDT
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation" (Nasdaq:NEPT) (TSX:NTB), announced today the release of the investigative report on the accident that took place November 8, 2012 at the Sherbrooke production plant. The report, made public by the Commission de la sante et de la securite du travail ("CSST" (the Quebec commission overseeing health and safety in the workplace), outlines the facts and alleged conclusions of the investigation and attributes some responsibility to the company. The report highlights that the exact cause of the accident could not be identified. In addition, it does not make any mention of additional fines or penalties against Neptune beyond the statement of offense notice seeking payment of a fine of approximately $60,000, previously received and disclosed by Neptune in the Fall of 2013.
Photo Release -- Neptune Provides Update on Plant Operating Permits
GlobeNewswire - Thu May 08, 8:31AM CDT
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation" (Nasdaq:NEPT) (TSX:NTB), provided an update today on the status of operating permits for its Sherbrooke, Quebec, Canada plant.
Friday's Big Swing Trades: NiSource, PolyOne, Republic Airways
at The Street - Fri May 02, 11:32AM CDT
The technicals and charts are suggesting NiSource, PolyOne, and Republic Airways as today's swing trades.
Neptune, Acasti and NeuroBioPharm reports departure of CEO Henri Harland
M2 - Tue Apr 29, 3:50AM CDT
Biotechnology company Neptune Technologies & Bioressources (NasdaqCM:NEPT) (TSX:NTB.TO), Acasti Pharma (NasdaqCM:ACST) (TSXV:APO.V) and NeuroBioPharm jointly disclosed on Monday the immediate resignation of its president and chief executive officer, Henri Harland.
Stock to Watch: Neptune Technologies & Bioressources-Ord Up 7.2% (NEPT)
Comtex SmarTrend(R) - Mon Apr 28, 11:40AM CDT
Neptune Technologies & Bioressources-Ord (AMEX:NEPT) is one of today's best performing low-priced stocks, up 7.2% to $2.39 on 1.1x average daily volume. Thus far today, Neptune Technologies & Bioressources-Ord has traded 497,000 shares, vs. average volume of 464,000 shares per day. The stock has outperformed the Dow (7.2% to the Dow's 0.4%) and outperformed the S&P 500 (7.2% to the S&P's 0.0%) during today's trading.
Enzymotec Ltd. Announces Signing of Final Settlement and License Agreement With Neptune
GlobeNewswire - Mon Apr 28, 7:46AM CDT
Enzymotec Ltd. (Nasdaq:ENZY) ("Enzymotec" or the "Company", a developer, manufacturer and marketer of innovative bio-active lipid ingredients, announced today that it signed a final settlement and license agreement with Neptune Technologies & Bioressources Inc. (Nasdaq:NEPT) ("Neptune" and Acasti Pharma Inc. ("Acasti". The International Trade Commission's ("ITC" investigation and related U.S. federal court actions will be terminated and dismissed accordingly.
Neptune, Acasti and NeuroBioPharm Announce Resignation of Chief Executive Officer
GlobeNewswire - Mon Apr 28, 7:01AM CDT
Neptune Technologies & Bioressources Inc. ("Neptune" (Nasdaq:NEPT) (TSX:NTB), Acasti Pharma Inc. ("Acasti" (Nasdaq:ACST) (TSX-V:APO) and NeuroBioPharm Inc. ("NeuroBio" today jointly announce the resignation of Henri Harland as President and Chief Executive Officer of Neptune, Acasti and NeuroBio with immediate effect. Mr. Harland remains a Director of Neptune, Acasti and NeuroBio.
Neptune and Enzymotec Conclude Final Patent Infringement Settlement ad License Agreement
GlobeNewswire - Sun Apr 27, 7:33PM CDT
Neptune Technologies & Bioressources Inc. ("Neptune" (Nasdaq:NEPT) (TSX:NTB) and Acasti Pharma Inc. ("Acasti" (Nasdaq:ACST) (TSX-V:APO), a Neptune subsidiary, announce that a final and binding patent infringement settlement and license agreement has been signed with Enzymotec Ltd. and Enzymotec USA, Inc. (collectively, "Enzymotec" that resolves the International Trade Commission's ("ITC" investigation of infringement of Neptune's composition of matter patents, related federal court actions initiated by Neptune against Enzymotec and its distributors, and various patent review proceedings requested by Enzymotec.
Neptune Obtains New US Patent Relating to Treatment of Alzheimer's
GlobeNewswire - Thu Apr 24, 11:11AM CDT
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation" (Nasdaq:NEPT) (TSX:NTB), announced today that the U.S. Patent & Trademark Office (the "USPTO" has granted Neptune a new continuation patent (U.S. Patent No. 8,680,080) relating to the treatment of Alzheimer's.
Neptune Responds to Enzymotec's Continuous Attempts to Shift Focus From ITC Investigation
GlobeNewswire - Mon Apr 21, 12:59PM CDT
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation" (Nasdaq:NEPT) (TSX:NTB), announced today that the United States Patent and Trademark Office ("USPTO" recently issued a Right of Appeal Notice in an inter partes reexamination of Neptune's U.S. Patent No. 8,030,348 ("the '348 Patent". Despite the USPTO's decision, the '348 Patent is still valid as Neptune has the right to appeal, which it intends to do.
Enzymotec Ltd. Announces a Final Decision Issued by the USPTO Rejecting All the Claims in Neptune's Patent
GlobeNewswire - Mon Apr 21, 7:00AM CDT
Enzymotec Ltd. (Nasdaq:ENZY) ("Enzymotec" or the "Company", a developer, manufacturer and marketer of innovative bio-active lipid ingredients, announced today that on April 18, 2014 the US Patent and Trademark Office ("USPTO" issued a final decision in the inter partes reexamination of Neptune Technologies & Bioressources, Inc. (Nasdaq:NEPT) ("Neptune" 8,030,348 patent rejecting all of the claims. Neptune may appeal this decision, but cannot submit any additional evidence or claim amendments.
Iroquois Capital Comments On Recent Schedule 13D Filing On Neptune Technologies & Bioresources Inc.
PR Newswire - Thu Apr 17, 7:39AM CDT
Iroquois Capital Management, LLC (together with its affiliates), a significant shareholder of Neptune Technologies & Bioressources Inc. "Neptune" (NASDAQ:NEPT), announced today that it had noted with interest and approval the Schedule 13D filing made recently by George W. Haywood and Messrs. Egan, O'Driscoll and Dobrich with respect to Neptune.
Neptune Announces Closing of CAD$2.5 Million Private Placement
GlobeNewswire - Fri Apr 04, 12:37PM CDT
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation" (Nasdaq:NEPT) (TSX:NTB), announced today the closing of a private placement of CAD$2,503,320 of common shares of Neptune (the "Shares" at a price of CAD$2.76 per Share, resulting in a total of 907,000 Shares being issued today (the "Private Placement".
Neptune & Acasti Give Update on Patent Litigations With Enzymotec
GlobeNewswire - Tue Apr 01, 1:25PM CDT
Neptune Technologies & Bioressources Inc. ("Neptune" (Nasdaq:NEPT) (TSX:NTB) and Acasti Pharma Inc. ("Acasti" (Nasdaq:ACST) (TSX-V:APO), a Neptune subsidiary, announce that they have been unable to conclude a final settlement agreement through mediation with Enzymotec Ltd. and Enzymotec USA, Inc. (collectively, "Enzymotec" that would resolve the International Trade Commission ("ITC" investigation into infringement of Neptune's composition of matter patents, as well as related federal court actions initiated by Neptune against Enzymotec and its distributors. Neptune and Acasti will now pursue Enzymotec through the ITC and the federal district court in Delaware.
Enzymotec Ltd. Provides Update on Patent Litigation With Neptune
GlobeNewswire - Tue Apr 01, 7:00AM CDT
Enzymotec Ltd. (Nasdaq:ENZY) ("Enzymotec" or the "Company", a developer, manufacturer and marketer of innovative bio-active lipid ingredients, announced today that following a mediation process with Neptune Technologies & Bioressources, Inc. (Nasdaq:NEPT) ("Neptune", in conjunction with litigation in the U.S. International Trade Commission ("ITC", and based on latest developments regarding Neptune's patents in the U.S. Patent and Trademark Office ("USPTO", it has decided that it will not continue its efforts to negotiate a final settlement agreement with Neptune.
Why Neptune Technologies (NEPT) Is Up Today
at The Street - Thu Mar 27, 2:11PM CDT
Neptune Technologies (NEPT) rose on Thursday after the company announced the reconstruction of its Sherbrooke, Quebec, Canada facility would conclude on April 7. The life sciences company is in the process of conducting equipment and safety tests at...
Traders Get Bullish on Shares of Neptune Technologies & Bioressources-Ord, Shares Up 6.7% (NEPT)
Comtex SmarTrend(R) - Thu Mar 27, 11:41AM CDT
Neptune Technologies & Bioressources-Ord (AMEX:NEPT) is one of today's best performing low-priced stocks, up 6.7% to $2.39 on 1.1x average daily volume. Neptune Technologies & Bioressources-Ord has traded 690,000 shares thus far today, vs. average volume of 632,000 shares per day. The stock has outperformed the Dow (6.7% to the Dow's 0.0%) and outperformed the S&P 500 (6.7% to the S&P's -0.2%) during today's trading.
Neptune Provides Update on Sherbrooke Plant
GlobeNewswire - Thu Mar 27, 6:45AM CDT
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation" (Nasdaq:NEPT) (TSX:NTB), announced today that reconstruction of its Sherbrooke, Quebec, Canada production facility will be completed April 7, 2014. Neptune is currently conducting equipment and safety related tests at the plant and employees are being trained. Preoperational testing will start early April 2014, with actual production commencing upon receipt of all outstanding permits.
Neptune to Hold Conference Call to Discuss Fourth Quarter and Fiscal Year Results
GlobeNewswire - 2 hrs 58 mins ago
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation"
(Nasdaq:NEPT) (TSX:NTB), announced today that it will be holding a conference call on Thursday May 22 at 9:00 AM (ET) to present its results for the fourth quarter and fiscal year ended February 28, 2014. Neptune Receives CSST Report
GlobeNewswire - Thu May 08, 9:53AM CDT
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation"
(Nasdaq:NEPT) (TSX:NTB), announced today the release of the investigative report on the accident that took place November 8, 2012 at the Sherbrooke production plant. The report, made public by the Commission de la sante et de la securite du travail ("CSST" (the Quebec commission overseeing health and safety in the workplace), outlines the facts and alleged conclusions of the investigation and attributes some responsibility to the company. The report highlights that the exact cause of the accident could not be identified. In addition, it does not make any mention of additional fines or penalties against Neptune beyond the statement of offense notice seeking payment of a fine of approximately $60,000, previously received and disclosed by Neptune in the Fall of 2013. Photo Release -- Neptune Provides Update on Plant Operating Permits
GlobeNewswire - Thu May 08, 8:31AM CDT
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation"
(Nasdaq:NEPT) (TSX:NTB), provided an update today on the status of operating permits for its Sherbrooke, Quebec, Canada plant. Friday's Big Swing Trades: NiSource, PolyOne, Republic Airways
at The Street - Fri May 02, 11:32AM CDT
The technicals and charts are suggesting NiSource, PolyOne, and Republic Airways as today's swing trades.
Neptune, Acasti and NeuroBioPharm reports departure of CEO Henri Harland
M2 - Tue Apr 29, 3:50AM CDT
Biotechnology company Neptune Technologies & Bioressources (NasdaqCM:NEPT) (TSX:NTB.TO), Acasti Pharma (NasdaqCM:ACST) (TSXV:APO.V) and NeuroBioPharm jointly disclosed on Monday the immediate resignation of its president and chief executive officer, Henri Harland.
Stock to Watch: Neptune Technologies & Bioressources-Ord Up 7.2% (NEPT)
Comtex SmarTrend(R) - Mon Apr 28, 11:40AM CDT
Neptune Technologies & Bioressources-Ord (AMEX:NEPT) is one of today's best performing low-priced stocks, up 7.2% to $2.39 on 1.1x average daily volume. Thus far today, Neptune Technologies & Bioressources-Ord has traded 497,000 shares, vs. average volume of 464,000 shares per day. The stock has outperformed the Dow (7.2% to the Dow's 0.4%) and outperformed the S&P 500 (7.2% to the S&P's 0.0%) during today's trading.
Enzymotec Ltd. Announces Signing of Final Settlement and License Agreement With Neptune
GlobeNewswire - Mon Apr 28, 7:46AM CDT
Enzymotec Ltd. (Nasdaq:ENZY) ("Enzymotec" or the "Company"
, a developer, manufacturer and marketer of innovative bio-active lipid ingredients, announced today that it signed a final settlement and license agreement with Neptune Technologies & Bioressources Inc. (Nasdaq:NEPT) ("Neptune" and Acasti Pharma Inc. ("Acasti". The International Trade Commission's ("ITC" investigation and related U.S. federal court actions will be terminated and dismissed accordingly. Neptune, Acasti and NeuroBioPharm Announce Resignation of Chief Executive Officer
GlobeNewswire - Mon Apr 28, 7:01AM CDT
Neptune Technologies & Bioressources Inc. ("Neptune"
(Nasdaq:NEPT) (TSX:NTB), Acasti Pharma Inc. ("Acasti" (Nasdaq:ACST) (TSX-V:APO) and NeuroBioPharm Inc. ("NeuroBio" today jointly announce the resignation of Henri Harland as President and Chief Executive Officer of Neptune, Acasti and NeuroBio with immediate effect. Mr. Harland remains a Director of Neptune, Acasti and NeuroBio. Neptune and Enzymotec Conclude Final Patent Infringement Settlement ad License Agreement
GlobeNewswire - Sun Apr 27, 7:33PM CDT
Neptune Technologies & Bioressources Inc. ("Neptune"
(Nasdaq:NEPT) (TSX:NTB) and Acasti Pharma Inc. ("Acasti" (Nasdaq:ACST) (TSX-V:APO), a Neptune subsidiary, announce that a final and binding patent infringement settlement and license agreement has been signed with Enzymotec Ltd. and Enzymotec USA, Inc. (collectively, "Enzymotec" that resolves the International Trade Commission's ("ITC" investigation of infringement of Neptune's composition of matter patents, related federal court actions initiated by Neptune against Enzymotec and its distributors, and various patent review proceedings requested by Enzymotec. Neptune Obtains New US Patent Relating to Treatment of Alzheimer's
GlobeNewswire - Thu Apr 24, 11:11AM CDT
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation"
(Nasdaq:NEPT) (TSX:NTB), announced today that the U.S. Patent & Trademark Office (the "USPTO" has granted Neptune a new continuation patent (U.S. Patent No. 8,680,080) relating to the treatment of Alzheimer's. Neptune Responds to Enzymotec's Continuous Attempts to Shift Focus From ITC Investigation
GlobeNewswire - Mon Apr 21, 12:59PM CDT
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation"
(Nasdaq:NEPT) (TSX:NTB), announced today that the United States Patent and Trademark Office ("USPTO" recently issued a Right of Appeal Notice in an inter partes reexamination of Neptune's U.S. Patent No. 8,030,348 ("the '348 Patent". Despite the USPTO's decision, the '348 Patent is still valid as Neptune has the right to appeal, which it intends to do. Enzymotec Ltd. Announces a Final Decision Issued by the USPTO Rejecting All the Claims in Neptune's Patent
GlobeNewswire - Mon Apr 21, 7:00AM CDT
Enzymotec Ltd. (Nasdaq:ENZY) ("Enzymotec" or the "Company"
, a developer, manufacturer and marketer of innovative bio-active lipid ingredients, announced today that on April 18, 2014 the US Patent and Trademark Office ("USPTO" issued a final decision in the inter partes reexamination of Neptune Technologies & Bioressources, Inc. (Nasdaq:NEPT) ("Neptune" 8,030,348 patent rejecting all of the claims. Neptune may appeal this decision, but cannot submit any additional evidence or claim amendments. Iroquois Capital Comments On Recent Schedule 13D Filing On Neptune Technologies & Bioresources Inc.
PR Newswire - Thu Apr 17, 7:39AM CDT
Iroquois Capital Management, LLC (together with its affiliates), a significant shareholder of Neptune Technologies & Bioressources Inc. "Neptune" (NASDAQ:NEPT), announced today that it had noted with interest and approval the Schedule 13D filing made recently by George W. Haywood and Messrs. Egan, O'Driscoll and Dobrich with respect to Neptune.
Neptune Announces Closing of CAD$2.5 Million Private Placement
GlobeNewswire - Fri Apr 04, 12:37PM CDT
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation"
(Nasdaq:NEPT) (TSX:NTB), announced today the closing of a private placement of CAD$2,503,320 of common shares of Neptune (the "Shares" at a price of CAD$2.76 per Share, resulting in a total of 907,000 Shares being issued today (the "Private Placement". Neptune & Acasti Give Update on Patent Litigations With Enzymotec
GlobeNewswire - Tue Apr 01, 1:25PM CDT
Neptune Technologies & Bioressources Inc. ("Neptune"
(Nasdaq:NEPT) (TSX:NTB) and Acasti Pharma Inc. ("Acasti" (Nasdaq:ACST) (TSX-V:APO), a Neptune subsidiary, announce that they have been unable to conclude a final settlement agreement through mediation with Enzymotec Ltd. and Enzymotec USA, Inc. (collectively, "Enzymotec" that would resolve the International Trade Commission ("ITC" investigation into infringement of Neptune's composition of matter patents, as well as related federal court actions initiated by Neptune against Enzymotec and its distributors. Neptune and Acasti will now pursue Enzymotec through the ITC and the federal district court in Delaware. Enzymotec Ltd. Provides Update on Patent Litigation With Neptune
GlobeNewswire - Tue Apr 01, 7:00AM CDT
Enzymotec Ltd. (Nasdaq:ENZY) ("Enzymotec" or the "Company"
, a developer, manufacturer and marketer of innovative bio-active lipid ingredients, announced today that following a mediation process with Neptune Technologies & Bioressources, Inc. (Nasdaq:NEPT) ("Neptune", in conjunction with litigation in the U.S. International Trade Commission ("ITC", and based on latest developments regarding Neptune's patents in the U.S. Patent and Trademark Office ("USPTO", it has decided that it will not continue its efforts to negotiate a final settlement agreement with Neptune. Why Neptune Technologies (NEPT) Is Up Today
at The Street - Thu Mar 27, 2:11PM CDT
Neptune Technologies (NEPT) rose on Thursday after the company announced the reconstruction of its Sherbrooke, Quebec, Canada facility would conclude on April 7. The life sciences company is in the process of conducting equipment and safety tests at...
Traders Get Bullish on Shares of Neptune Technologies & Bioressources-Ord, Shares Up 6.7% (NEPT)
Comtex SmarTrend(R) - Thu Mar 27, 11:41AM CDT
Neptune Technologies & Bioressources-Ord (AMEX:NEPT) is one of today's best performing low-priced stocks, up 6.7% to $2.39 on 1.1x average daily volume. Neptune Technologies & Bioressources-Ord has traded 690,000 shares thus far today, vs. average volume of 632,000 shares per day. The stock has outperformed the Dow (6.7% to the Dow's 0.0%) and outperformed the S&P 500 (6.7% to the S&P's -0.2%) during today's trading.
Neptune Provides Update on Sherbrooke Plant
GlobeNewswire - Thu Mar 27, 6:45AM CDT
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation"
(Nasdaq:NEPT) (TSX:NTB), announced today that reconstruction of its Sherbrooke, Quebec, Canada production facility will be completed April 7, 2014. Neptune is currently conducting equipment and safety related tests at the plant and employees are being trained. Preoperational testing will start early April 2014, with actual production commencing upon receipt of all outstanding permits. 
